NYSEAMERICAN:AZTR Azitra (AZTR) Stock Price, News & Analysis $0.57 -0.01 (-1.22%) (As of 02:52 PM ET) Add Compare Share Share Today's Range$0.56▼$0.5850-Day Range N/A52-Week Range$0.49▼$68.40Volume93,491 shsAverage Volume1.04 million shsMarket Capitalization$4.37 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsHeadlinesInsider TradesOwnershipShort InterestStock AnalysisChartEarningsHeadlinesInsider TradesOwnershipShort Interest Get Azitra alerts: Email Address Ad DTII want to be very real with youListen, I don’t come at my readers this direct very often, but here goes nothing: There is one strategy that has helped change my life and I’d like to think it has changed the lives of some of my readers, too. We’ve had success stories but I won’t even show you here because I don’t want you to get unrealistic expectations since individual results do vary. But the point is, this thing is the real deal. There’s a reason I consider it my flagship, even with all the market advantages I’ve discovered in recent years.Watch this URGENT training here! About Azitra Stock (NYSEAMERICAN:AZTR)Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.Read More AZTR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AZTR Stock News HeadlinesSeptember 7, 2024 | finance.yahoo.comAzitra to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceAugust 28, 2024 | finance.yahoo.comAzitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton SyndromeSeptember 16, 2024 | DTI (Ad)Weird phenomenon on AMZN stockWhat would you do if you knew that you could have bought Amazon on May 25th every year and walked away with a win?August 28, 2024 | markets.businessinsider.comAzitra Inc (AZTR) Receives a Buy from Maxim GroupAugust 24, 2024 | finance.yahoo.comAZTR: First ATR-12 Patient ScreenedAugust 23, 2024 | finance.yahoo.comAzitra Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR InhibitorsAugust 21, 2024 | finance.yahoo.comAzitra, Inc. (AZTR)August 21, 2024 | businesswire.comAzitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton SyndromeSeptember 16, 2024 | DTI (Ad)Weird phenomenon on AMZN stockWhat would you do if you knew that you could have bought Amazon on May 25th every year and walked away with a win?August 16, 2024 | markets.businessinsider.comMcCarthy’s Buy Rating on Azitra Inc: Strong Pipeline and Strategic Financial PositioningJuly 30, 2024 | msn.comAZTR: Get Some Skin in the GameJuly 26, 2024 | finance.yahoo.comCORRECTING and REPLACING Azitra, Inc. Announces Closing of $10.0 Million Public OfferingJuly 25, 2024 | benzinga.comWhy Azitra Stock Is CrashingJuly 24, 2024 | investorplace.comWhy Is Azitra (AZTR) Stock Down 75% Today?July 24, 2024 | finance.yahoo.comKSS Line Ltd. (044450.KS)July 23, 2024 | benzinga.comWhy Azitra Stock Is Moving Higher On TuesdayJuly 23, 2024 | investorplace.comWhy Is Azitra (AZTR) Stock Up 315% Today?July 23, 2024 | finance.yahoo.comAzitra, Inc. Strengthens Global Intellectual Property Portfolio with Newly Granted and Allowed PatentsSee More Headlines Receive AZTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Azitra and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2024Today9/16/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:AZTR CUSIPN/A CIKN/A Webazitrainc.com Phone203-646-6446FaxN/AEmployees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,280,000.00 Net Margins-1,644.90% Pretax Margin-2,435.53% Return on Equity-278.76% Return on Assets-176.66% Debt Debt-to-Equity Ratio0.01 Current Ratio0.77 Quick Ratio0.77 Sales & Book Value Annual Sales$690,000.00 Price / Sales6.41 Cash FlowN/A Price / Cash FlowN/A Book Value$7.23 per share Price / Book0.08Miscellaneous Outstanding Shares7,630,000Free Float912,000Market Cap$4.43 million OptionableNot Optionable Beta-1.84 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Francisco D. Salva (Age 53)President, CEO & Director Comp: $427.03kMr. Travis M. Whitfill M.P.H. (Age 34)Ph.D., Co-Founder, COO & Director Comp: $161.61kMr. Norman Staskey (Age 54)CFO, Treasurer & Secretary Comp: $314.02kDr. Mark SampsonChief Scientific OfficerKey CompetitorsSol-Gel TechnologiesNASDAQ:SLGLCocrystal PharmaNASDAQ:COCPImmunoPrecise AntibodiesNASDAQ:IPAKALA BIONASDAQ:KALASynlogicNASDAQ:SYBXView All CompetitorsInsidersNorm StaskeyBought 1,586 shares on 3/29/2024Total: $9,991.80 ($6.30/share)Francisco D SalvaBought 11,110 shares on 2/13/2024Total: $99,990.00 ($9.00/share)Travis WhitfillBought 500 shares on 2/13/2024Total: $4,500.00 ($9.00/share)Norm StaskeyBought 110 shares on 2/13/2024Total: $990.00 ($9.00/share)View All Insider Transactions AZTR Stock Analysis - Frequently Asked Questions How have AZTR shares performed this year? Azitra's stock was trading at $2.7660 on January 1st, 2024. Since then, AZTR shares have decreased by 79.3% and is now trading at $0.5729. View the best growth stocks for 2024 here. How were Azitra's earnings last quarter? Azitra, Inc. (NYSEAMERICAN:AZTR) released its quarterly earnings data on Monday, August, 12th. The company reported ($2.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.59) by $0.15. The firm earned $0.01 million during the quarter. Azitra had a negative trailing twelve-month return on equity of 278.76% and a negative net margin of 1,644.90%. When did Azitra's stock split? Azitra's stock reverse split on Monday, July 1st 2024. The 1-30 reverse split was announced on Monday, July 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of Azitra? Shares of AZTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:AZTR) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukra...Capital Trends | SponsoredBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Azitra, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Azitra With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
